Zelda Therapeutics received approval from the Therapeutics Goods Administration and the Human Research Ethics Committee to trial its medicinal cannabis formulations on people with chronic insomnia, reports Startsat60.
In a statement, Zelda said patient data from the US and Chile showed anecdotal evidence that medical marijuana was beneficial to people with chronic insomnia, and that it would now test the formulations on Australians who had long-term issues with falling and staying asleep.
